Price list of Indian and Bengali version of Sottorashi cloth

Sotorasib (AMG510, Sotorasib) is a targeted drug developed for the KRAS G12C mutation. It was developed by Amgen. It is the first targeted inhibitor successfully approved for the treatment of this mutant type of non-small cell lung cancer (NSCLC). In the U.S. and European markets, the drug has been approved for patients with KRAS G12C mutated lung cancer who have received at least one systemic treatment in the past. The drug is taken once a day at 960 mg each time, which is a long-term maintenance medication. Its efficacy is highly targeted and its side effects are relatively mild, opening up a new situation in the field of precision treatment of lung cancer.

However, in terms of price, the original drug sotoracib is expensive. Since it has not yet been officially launched in China, patients can only obtain it through cross-border drug purchases. The price of the European version of sotorasibu is extremely high, with the price of each box (120mg, 240 tablets) being about more than RMB 80,000, which is far beyond the affordability of ordinary patient families. At present, there is no original drug or generic drug of sotorasibu approved for production in India, which means that the drug is not officially sold in India.

In contrast, the Bangladeshi version of the generic drug has been copied and put on the market by well-known local pharmaceutical companies. It uses the same active ingredients and dosage forms as the original drug. The common specification is120mg × 56 tablets. Since Bangladesh is not subject to international patent restrictions, its generic drugs can be launched earlier and significantly reduce costs. Under normal circumstances, the market price of a box of Bangladeshi version of Sotorasibu generic medicine is about RMB 1,000 to RMB 2,000. The price fluctuates due to exchange rates, procurement channels and transportation costs. Since the price is significantly lower than the original drug, this generic version has become an important choice for most patients to purchase drugs across borders.

It should be noted that although the ingredients of Bangladeshi generic drugs are consistent with those of the original research, they have not passed the review by China's National Food and Drug Administration (NMPA). Patients should use them under the guidance of a doctor to ensure drug quality and treatment safety. At the same time, it is recommended to conduct KRAS G12C mutation testing before use to determine whether sotorasibu is suitable for use, so as to avoid ineffective treatment and unnecessary drug expenses.

Reference materials:https://www.lumakras.com/